Study of dimethyl fumarate for preserving insulin in new-onset type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests the drug dimethyl fumarate (an oral medication already used for other conditions) to see if it can help people newly diagnosed with type 1 diabetes keep making their own insulin for longer. The goal is to slow down the immune attack on the pancreas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with type 1 diabetes within the last 100 days (about 3 months).
- A blood test shows your body still makes some insulin (C-peptide at least 200 pmol/L).
- You have at least two diabetes-related autoantibodies in your blood.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You are not taking immune-suppressing medications now or in the past 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
This study tests if denosumab, a drug normally used for bone health, can help preserve your body's own insulin production in type 1 diabetes. It might slow the loss of insulin-making cells, helping you maintain better blood sugar control over time.
This study tests if verapamil (a common blood pressure medication) can help children newly diagnosed with type 1 diabetes keep making their own insulin for longer. It aims to preserve the body's own insulin-producing cells, which may reduce the amount of insulin injections needed.
This study tests a new drug called SAB-142, which aims to stop the immune system from attacking insulin-making cells in type 1 diabetes. It may help preserve your body's ability to make insulin. The trial will check if the drug is safe and effective.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
This Phase 1/2 study tests whether CELZ-201 is safe and can help the body keep making some of its own insulin in people who were recently diagnosed with type 1 diabetes. You may be eligible if your diabetes started within the past year and your tests show you still have some insulin-making activity.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.